EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Emerging role of radiopharmaceutical therapy in oncology: advances, challenges, and future directions

Laura Ordas, Sean Foster, Phuc Pham, Andy Ollendorff, Varun Gnanasekar, Mahmoud Toulany, Quaovi H Sodji iD

JNCI Cancer Spectrum · 09.05.2026 · 10 (3)

DOI: 10.1093/jncics/pkag056 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 02.06.2026. Verfasst von Laura Ordas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Neuroendocrine Tumors, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceutical therapy has transformed cancer management by enabling systemic delivery of ionizing radiation via molecularly targeted pharmaceutics, complementing external beam radiotherapy, which primarily treats localized, radiographically defined lesions. By coupling diagnostic imaging with therapy, in a “radiotheranostic” paradigm, radiopharmaceutical therapy supports patient-specific target selection, dosimetry, and on-treatment monitoring. Progress in target discovery, radioligand chemistry, and optimization of pharmacokinetics and biodistribution has improved efficacy and safety, culminating in US Food and Drug Administration approvals of [177Lu]Lu-PSMA-617 (Pluvicto) for metastatic castration-resistant prostate cancer and [177Lu]Lu-DOTA-TATE (Lutathera) for neuroendocrine tumors. These successes highlight radiopharmaceutical therapy’s expanding role across oncology. This review summarizes the evolution of radiopharmaceutical therapy from early clinical milestones to modern regulatory approvals, then surveys emerging radioligands directed at new molecular pathways. We also discuss strategies to enhance therapeutic response including rational combinations with DNA damage response agents such as poly(adenosine diphosphate–ribose) polymerase inhibitors or immunotherapies. Finally, we outline key challenges such as optimal patient selection, dosimetry standardization, therapeutic resistance, and access and highlight a few ways to accelerate broader clinical integration and continued innovation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsNeuroendocrine TumorsProstatic Neoplasms, Castration-ResistantHumansRadioisotopesMaleDipeptidesMolecular Targeted TherapyLutetiumOrganometallic CompoundsOctreotideProstate-Specific Antigen

Substanzen

RadiopharmaceuticalsRadioisotopesDipeptideslutetium (177Lu) vipivotide tetraxetanlutetium Lu 177 dotatateLutetiumLutetium-177Organometallic CompoundsOctreotideProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
  • Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States.
  • William S. Middleton Veterans Hospital, Radiation Oncology, Madison, WI, United States.

ORCID-Profile: Quaovi H Sodji

Förderung

  • NIH HHS
  • NIH

Zitieren

APA

Ordas, L., Foster, S., Pham, P., Ollendorff, A., Gnanasekar, V., Toulany, M., & Sodji, Q. H. (2026). Emerging role of radiopharmaceutical therapy in oncology: advances, challenges, and future directions. JNCI Cancer Spectrum, 10(3). https://doi.org/10.1093/jncics/pkag056

Vancouver

Ordas L, Foster S, Pham P, Ollendorff A, Gnanasekar V, Toulany M, et al. Emerging role of radiopharmaceutical therapy in oncology: advances, challenges, and future directions. JNCI Cancer Spectrum. 2026;10(3). doi:10.1093/jncics/pkag056

BibTeX
@article{Ordas2026,
  author = {Ordas, Laura and Foster, Sean and Pham, Phuc and Ollendorff, Andy and Gnanasekar, Varun and Toulany, Mahmoud and Sodji, Quaovi H},
  title = {Emerging role of radiopharmaceutical therapy in oncology: advances, challenges, and future directions},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.1093/jncics/pkag056}
}
Kostenlos starten →